Pancreaze (pancrelipase) capsules are only available in brand-name form. However, after the exclusivity rights for the drug expire in April 2015, companies may be allowed to manufacture a generic Pancreaze product. Although pancrelipase is considered the "generic name" for Pancreaze, it is simply the active ingredient in the drug and not a generic version of it.
Pancreaze® (pancrelipase) is a prescription medication approved for the treatment of pancreatic digestive enzyme deficiencies, such as the type of deficiency that occurs with cystic fibrosis. It is taken by mouth with each meal.
Pancreaze is made by Nordmark Arzneimittel GmbH & Co. KG (a German manufacturer) for Janssen Pharmaceuticals, Inc. It is protected from generic competition in the United States by exclusivity rights, which are not exactly the same as patents.
The exclusivity rights for Pancreaze are set to expire in April 2015. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Pancreaze uses. Once Pancreaze is no longer protected by exclusivity rights, there may be several companies that manufacture a generic Pancreaze drug.
No -- pancrelipase is the active ingredient in Pancreaze, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." There are a few other brand-name pancrelipase drugs, but they are not directly interchangeable; different pancrelipase products have different mixtures of the various different enzymes.